CPA
LAB icon

Capital Performance Advisors’s Standard BioTools LAB Stock Holding History

Capital Performance Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-197
Closed -$380 – 1505
2024
Q3 		$380 Buy
+197
New +$386 ﹤0.01% 2371

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Capital Performance Advisors's LAB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 197 shares — an estimated $380 sold.

Capital Performance Advisors first reported a position in LAB in Q3 2024 and held it in 1 quarter. The position peaked at $380 in Q3 2024. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 197 Standard BioTools shares in Q4 2024, an estimated $380.
  • Capital Performance Advisors first reported a position in Standard BioTools in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Standard BioTools position peaked at $380 in Q3 2024.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.